COMMUNIQUÉS West-GlobeNewswire

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
27/04/2026
WAYNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
Tessera Therapeutics to Present New Preclinical Data Supporting In Vivo Program in Sickle Cell Disease and Advancements in In Vivo CAR-T Applications at the American Society of Gene and Cell Therapy 29th Annual Meeting
27/04/2026
SOMERVILLE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Tessera Therapeutics (“Tessera”), the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced four presentations [...]
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
27/04/2026
PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching targeted cell therapies designed specifically for [...]
ElevateBio to Present Nine Abstracts Showcasing Advancements Across its Gene Editing Platform at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
27/04/2026
– Posters detail large gene insertion and epigenetic editing capabilities, expanding ElevateBio’s gene editing toolbox – Additional presentations highlight protein engineering expertise, off-target assessment strategies [...]
Arbor Biotechnologies to Present Expansion of CNS Editing Platform Capabilities at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
27/04/2026
- Oral presentation highlights novel compact RT editor demonstrating first preclinical in vivo proof of concept for precise gene editing in the CNS delivered via a single AAV - Poster presentations showcase deepening [...]
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
27/04/2026
PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical naïve and [...]
Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
27/04/2026
Oral and poster presentations highlight progress across cardiac genetic medicine pipeline and optimized, Sf9-baculovirus AAV manufacturing platform NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. ( [...]
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
27/04/2026
In vitro data demonstrated self-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 (ssAAV9), supporting the ability to effectively deliver TSHA-102 to the CNS [...]
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
27/04/2026
A 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years (n=5) receiving icovamenib 200 mg, with a clear dose response observed vs 100 mg (n=6) Persistence observed through [...]
Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal
27/04/2026
WARREN, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced continued progress within its artificial intelligence initiative, Tevogen.AI, including [...]
AGC Biologics Wins 2026 Fierce Outsourcing Award for Leadership in Regulatory and Quality Compliance
27/04/2026
Global CDMO recognized for exceptional quality systems and regulatory track record; named finalist in Excellence in Client Service & Partnership and Manufacturing Operations categories SEATTLE, April 27, 2026 (GLOBE [...]
IBA – ACQUISITION D’ACTIONS PROPRES
27/04/2026
Louvain-la-Neuve, Belgique, 27 avril 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") [...]
IBA – ACQUISITION OF OWN SHARES
27/04/2026
Louvain-la-Neuve, Belgium, April 27 th , 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
27/04/2026
Déclaration de transactions sur actions propres Paris, France (27 avril 2026, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 30 avril 2025, EssilorLuxottica déclare que le 24 avril 2026, les [...]
EssilorLuxottica: Disclosure of transactions in own shares
27/04/2026
Disclosure of transactions in own shares Paris, France (April 27, 2026 - 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 30, 2025, EssilorLuxottica declares that on [...]
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
27/04/2026
Ghent, Belgium, April 27, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE - REGULATED INFORMATION 27 April 2026, 6:00 pm CEST Ghent, Belgium, 27 April 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " [...]
AB Science annonce un accord final sur la renégociation des modalités de remboursement de ses emprunts avec l’ensemble de ses créanciers financiers
27/04/2026
COMMUNIQUE DE PRESSE AB SCIENCE annonce un accord final sur la renégociation des modalités de remboursement de ses emprunts avec l’ensemble de ses créanciers financiers AB Science est parvenue à un accord définitif avec [...]
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors
27/04/2026
PRESS RELEASE AB SCIENCE announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors AB Science has reached a final agreement with its financial creditors [...]
Virbac : Communiqué de mise à disposition du Rapport Annuel de Virbac au 31 décembre 2025
27/04/2026
Communiqué de mise à disposition du Rapport Annuel de Virbac au 31 décembre 2025. Le Groupe annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers son Rapport Annuel au format [...]

Pages